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1162-103 Effect of Left Ventricular Function on Long-Term Left 
Ventricular Pacing and Sensing Threshold 
Huno-Fat Tsa, Chu-Pak Lau, Vince Paul, Giuseppe Boriani, Schuchert Andreas, Juan 
Leal Del Ojo, K. Malinowski, Jean-Jacques Blanc, Department of Medicine, University of 
/'long Kong, Queen Mary Hospital, l-long Kong, l-long Kong. 
Background. The effect of left ventdcular (LV) systolic function on the long-term LV pec-- 
ing and sensing threshold is unclear. 
Methods. We studied the effect of LV ejection fraction (LVEF) on the LV pacing and sens- 
ing threshold in 56 patients (pts)(mean age: 70.2-+10.5 years) enrolled in study evaluat- 
ing the safety and efficacy of the Aescula TM Left Heart Lead, Model 1055K (St. Jude 
Medical, USA). 49 pts (88%) and 7 pts (12%) were implanted for conventional pace- 
maker (sick sinus syndrome=14, heart block=20 or atrial fibrillation 9) and heart failure 
indications, respectively. 28 pts had LVEF _<40% (Gp 1), and remaining 28 patients had 
LVEF >40% (Gp 2). The LV pacing and sensing threshold, and lead impedance were 
measured during implant and at 3 month (M) follow up. 
Results. The LV pacing lead was successfully implanted in all pts without any dislodge- 
ment on follow-up. At implant, Gp 1 had a significantly lower R wave amplitude and lead 
impedance, but a similar LV pacing threshold vs. Gp 2 (Table 1). At 3 M, Gp 1 had a sig- 
nificantly higher LV pacing threshold but similar R wave amplitude and lead impedance 
vs. Gp 2 (Table 1 ). 
Conclusions. Our results suggest that LV sytolic function have a significant impact on the 
long-term LV pacing threshold. Depsite the similar LV pacing threshold during implant, 
pts with impaired LV function had significant increase in LV pacing threshold on follow- 
up. This finding has important implication on programming of pacing output to ensure LV 
capture for pacing therapy in congestive heart failure. 
LV Pacing Threshold R Wave Impedance (~) 
(V at 0.5 ms) Amplitude (mV) 
Mean LVEF Implant 3 M Implant 3 M Implant 3M 
(%) 
Gp 1 27¢8 1.3_+0.7 2.2±1.2 + 7.0±3.2 6.6±3.9 687±193 708±195 
Gp2 62¢10 1.5¢1.0 1.6_+0.8" 9.7_+3.4* 8.0-J:4.0 875±344" 739-+147 
(*p<0.05 vs. Gp 1, +p<0.05 vs. Implant) 
1162-104 Short-Term Effects of Cardiac Resynchronization on 
Brain Natrluretic Peptide Release in Patients With 
Systol ic Heart Failure and Ventricular Conduct ion 
Diaturbance 
Karsten Filzmaier. Anil M. Sinha, Ole A. Breithardt, Hugo Stiegler, Yudko Fischer, J5rgen 
Graf, Karl Mischke, Christoph Stellbrink, University Hospital Aachen, Medical Clinic/, 
Aachen, Germany, University Hospital Aachen, Department of Clinical Chemistry, 
Aachen, Germany. 
Background: Brain natriuretic protein (BNP) is highly expressed in pathological hemody- 
namic conditions and correlates with left ventricular ejection fraction (EF), left ventricular 
wall stress and pressure or volume overload. Cardiac resynchronization by biventricular 
(BiV) pacing has recently been shown to improve hemodynamics acutely in patients (pts) 
with advanced systolic heart failure (HF) and left bundle branch block (LBBB). We inves- 
tigated the effects of short-term BiV-pacing on BNP levels in pts with HF. 
Methods: 12 pts. (7 male, 5 female) with severe HF (mean EF 24 +/- 5 %, NYHA It 3 pts, 
NYHA III 8 pts, NYHA IV 2 pt.) who underwent implantation of a BiV pacemaker were 
included in the study. 7 pts suffered from dilative and 5 from ischemic cardiomyopathy. 
BNP levels were determined with the Triage BNP test (Biosite Diagnostics, San Diego, 
USA). Blood samples for BNP were taken at rest on the day before surgery and 4-6 days 
after pacemaker implantation after continuous BiV pacing. The pacemaker was pro- 
grammed to the atrial triggered BiV paced (VDD) mode immediately after implantation 
with an atrioventricular delay of 121 ± 21 ms. As BNP levels are elevated in patients with 
impaired renal function, Creatinine and blood urea nitrogen (BUN) levels were measured 
at the same time points. Left ventdcuiar EF was determined echocardiographically. 
Results: None of the pts had severely impaired renal funtion at baseline (Creatinine: 1,4 
± 0,4 mg/dl; BUN: 61 ± 21 mg/dl). Initial BNP levels were abnormal in all pts. with a mean 
of 537 ± 306 pg/ml (range 102-1030 pg/rnl). After 4-6 days of continuous BiV pacing BNP 
levels decreased significantly to 255 ± 200 pg/ml (range 32-667 pg/ml, p<0,005). Craati- 
nine and BUN levels showed no significant increase after surgery (1,4 ± 0,4 mg/dl, 62 ± 
32 mg/dl; p=n.s.). 
Conclusion: Cardiac resynchronization by BiV pacing leads to a significant decrease in 
BNP release as an indicator for improved hemodynamics and a better neurohormonal 
status after short term BiV pacing. Thus, rnonitoring BNP can potentially be used as a 
marker for the therapeutic effect of BiV pacing in pts. with advanced HF and ventricular 
conduction disturbance. 
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1162-119 Biventrlcular Pacing In Patients With Hypertrophic 
Cerdlomyopethy: Beneficial Effect on Exercise 
Tolerance and Symptomatic Status 
Christooher A. Rinaldi. Cliff A. Bucknail, Ron D. Simon, Pier Lambiase, Artur Baszko, 
Julian Bostock, Donna Elliott, Jaswinder S. Gill, Guys and St Thomas NHS Trust, 
London, United Kingdom. 
Background: Biventdcular (BIV) pacing is beneficial in patients with heart failure and pro- 
longed QRS duration. We assessed its benefit in patients with hypertrophic ardiomyop- 
athy (HCM) and intraventricular conduction delay with normal systolic function. 
Methods: Seven patients aged 57±8yrs with HCM and prolonged QRS underwent BIV 
pacing with placement of electrodes in the right ventdcular (RV) apex and a branch of the 
coronary sinus to allow left ventdcular pacing. An atrial electrode was also inserted to 
achieve sequential BIV pacing with a short AV delay of 78 msecs. Symptomatic status 
and treadmill exercise tolerance was assessed after 1 month in each pacing modality 
Results: There was a significant improvement in NYHA class with both active pacing 
modalitias although the improvement appeared greater in BIV mode. When symptomatic 
status was assessed using the Minnesota Living with Heart Failure questionnaire there 
was only a statistically significant improvement with BIV pacing as compared to baseline 
(71 ±3 vs 40±33, p<0.05). Exercise duration increased with both active pacing modalities 
but only in BIV pacing did this reach statistical significance (231±171 vs 300¢208, 
p<0.05). Conclusion: BIV pacing in patients with HCM and prolonged QRS has beneficial 
effects on both exercise tolerance and symptoms which exceeds that of RV pacing. 
1162-120 Pacing Mode and Pacing Site Determine the Amount of 
Hemodynamic Response in Resynchronization Therapy 
Jueroen Voat. Barbara Lamp, Johannes Heintze, Bert Hansky, Leon Krater, Frank 
Warzok, Reiner Koerfer, Dieter Horstkotte, Heart Center North Rhine-Westphalia, Bad 
Oeynhausen, Gerrnan v 
In resynchronisation therapy the posterolateral (PL) free wall has been identified as the 
optimal pacing site in contrast to the anterior or inferior wall. Although in the majority of 
clinical studies patients (pts.) are paced biventricular (BiV), no data are available on indi- 
vidual differences between left ventricular (LV) and BiV pacing. 
We report on the preoperative hemodynamic test procedure in 86 heart failure pts. with 
sinus rhythm (age 62±9 years, 24 women, NYHA 3.1, 50 pts. with DCM, 34 pts. with 
CAD, QRS-width 192±22 ms, PQ interval 222±42 ms). Artedal pulse pressure (PP) was 
measured during atrio-LV and atrio-BiV pacing (VAT-mode) at different AV-delays using 
electrophysiology catheters in right atrium, right ventdcular apex (RVA) and poaterolat- 
eral coronary veins (CV). In 14 pts. 2 alternate PL CV and in 17 pts. RV outflow tract 
(RVOT) were tested. 
13 pts were non responders (PP response below 10%). At the optimal AV-delay the best 
hemodynamic response was BV in 41, LV in 30 and BV with RVOT in 2 pts. The individ- 
ual difference in PP increase between BV- and LV pacing mode at optimal AV-delay was 
3 to 59%. 13 pts. showed response only by changing from BiV to LV (7 pts.), from LV to 
BiV (4), and from BiV+RVA to BiV+RVO (2 pts.). In 14 pts. with alternate PL veins the dif- 
ference of PP increase between those tested veins was 4 to maximal 18%. In 4 pts. a 
sufficient response could only be seen by testing the second PL vein. The rosponders 
were implanted and programmed to the identified optimal mode and site. 
Without preoperative testing of pacing mode and site 30% (26/86) of pts. would have 
been implanted without significant acute response. 43 % (32/73) of respooders did not 
have their optimal hemodynamic response at BiV pacing. Thus preimplant esting of dif- 
ferent sites including alternate PL CV and RVOT has an impact on implantation fre- 
quency (economics) and probably on clinical follow up and results of outcome studies. 
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857-1 Molecular Autopsy for HERG Defects In Sudden Infant 
Death Syndrome 
Michael J. Ackerman. Blake D. Anson, David J. Tester, Jeffrey A. Towbin, William Q. 
Stumer, Craig T. January, Mayo Clinic/Mayo Foundation, Rochester, Minnesota, 
University of Wisconsin, Madison, Madison, Wisconsin. 
Background: Fatal arrhythmias from occult long QT syndrome (LQTS) may be responsi- 
ble for some cases of sudden infant death syndrome (SIDS). Recently, we have estab- 
lished cardiac ion channelopathies as a pathogenic mechanism for SIDS, identifying 
defects in the cardiac sodium channel, BCN5A, in 2% of cases. Here, the prevalence and 
functional properties of putative SIDS-cauaing mutations in the cardiac potassium chan- 
nel gene, HERG (KCNH2), are determined. 
Methods: Postmortem molecular analysis was performed on 93 cases of SIDS or unde- 
termined infant death identified by the Medical Examiner's Office of the Arkansas State 
Crime Laboratory between September 1997 and August 1999. Genomic DNA was 
extracted from frozen myocardium and subjected to HERG mutational analysis using 
polymerase chain reaction, denaturing high performance liquid chromatography, and 
DNA sequencing. Missenss mutations were incorporated into the expression vector 
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pcDNA3-HERG by site-directed mutagenesis, expressed by transient transfection of 
human embryonic kidney ceils, and characterized electrophysiologically. 
Results: 8 of the 93 cases of SIDS possessed 4 novel nonsynonymous ingle nucteotide 
polymorphisms (SNPs, amino acid variants). However, 3 of the variants were identified in 
ethnic-matched controls. A putative SIDS-causing HERG mutation was found in exon 4 
from a 6-month-old Caucasian male. This N-terminal mutation was not present in 200 
alleles from Caucasian controls. Functionally, this mutation results in significantly 
decreased levels of whole cell current compared to wild type. 
Conclusions: Approximately 1% of this prospective, population-based cohort of SIDS 
cases had an identifiable HERG channel defect. This study implicates cardiac eotassium 
channels in SIDS for the first time. In addition, the study illustrates the importance of eth- 
nic-matched controls to avoid the erroneous assignment of novel nonsynonymous SNPs 
as putative BIDS-causing mutations. 
10:45 a.m. 
857-2 Effect of Phenylephrine Provocation on Dispersion of 
Repolarization in Congenital Long QT Syndrome 
Anant Khositseth, Jan Nemec, Joseph Hejiik, Win K. Shen, Michael J. Ackerman, Mayo 
Clinic, Rochester, Minnesota. 
Background: Syncope or sudden cardiac arrest is associated with sympathetic stimula- 
tion in LQT1. LQT2 and LQT3 patients are more susceptible to arrhythmias at lower 
heart rates. Spatial dispersion of repolarization is estimated by QT dispersion (QTd = 
QTmax - QTmin) whereas transmurel dispersion of repolarization (TDR) is estimated by 
the interval from T peak to T end (Tp-e). This study compares the effect of phenylephrine 
on QTd and TDR in genotyped long QT syndrome (LQTS) to control (C). 
Methods: 17 patients (12 F, 26,9 + 11.6 years) with LQT1, 15 patients (8 F, 26,7 + 12.9 
years) with LOT2/3, and 18 age- and gender- matched normal controls (10 F, 26.3 + 12.3 
years) were given a phenylephrine bolus intravenously at 2 mcg/kg. At baseline and at 
peak phenylephrine ffect, BP, QT, RR, Bazett's QT c, precordial QTd, and Tp-e intervals 
were determined blinded to the patient's clinical and genotype status. 
Results: Baseline QT intervals (482!-45 ms and 542+76 vs, 414±27) and OTc (476+26 
ms and 516+46 vs. 422+28) were significantly longer in LQT1 and LQT2/3 compared to 
control (p < 0.0001). Baseline QTd and Tp-e in LQT2/3 were greater than both LQT1 and 
control: QTd = 84+29 ms (LQT2/3), 53+25 (LQT1), 44+15 (C), p < 0.0001 and Tp-e = 
121:tr.28 ms (LQT2/3), 99+21 (LOT1), and 90+11 (C), p < 0.0003. Phenylephrine signifi- 
cantly increased blood pressure and slowed heart rate in all groups as expected. Phe- 
nylephrine exerted no significant effect on either QTd or Tp-e in all groups, Subgroup 
analysis of svmctomatic LOT1 (n=5) and symptomatic LQT2/3 (n=4) demonstrated a sig- 
nificant change in TDR following phenylephrine. In symptomatic LQT1, Tp-e decreased 
by 9 + 27 ms whereas Tp-e increased by 16 + 22 in symptomatic LOT2/3, p < 0.02). Phe- 
nylephrine tended to impact QTd differentially as well between symptomatic LOT1 and 
symptomatic LQT2/3 (-16 + 11 vs. 4 + 12). 
Conclusions: Phenylephrine-induced bredycardia decreased TDR in symptomatic 
LOT1 but increased TDR in symptomatic LOT2/3. The observed effects of phenylephrine 
are consistent with the protective effect of beta-bleeker therapy in LQT1 and the 
increased arrhythmogenicity noted during non-exertional states in LQT2/3. 
11:00 a.m, 
857-3 The Mechanism of Ventricular Arrhythmia on a Canine 
Isolated Blood-Perfused Brugada Syndrome Model 
Masaomi Kimura, Takao Kobayashi, Shingen Ohweda, Shingo Saseki, Tomonori 
Igarashi, Atsushi Iwasa, Shigeru Motomura, Ken Okumura, Hirosaki Universi~ Hirosaki, 
Japan. 
Background: Brugada syndrome is characterized by ST elevation in the right precordial 
leads and high incidence of ventricular arrhythmlas (VA). Phase 2 reentry was suggested 
as a mechanism for VA in the canine right ventricular (RV) preparation perfused with 
Tyrode solution. 
Methods: In an isolated canine RV preparation cross-circulated with arterial blood of the 
support dog (n=8), we simultaneously recorded a transmural ECG and 96 bipolar electro- 
grams using two rectangular plaque electrodes (35x30mm, each contained 48 elec- 
trodes) attached to the endocardial (ENDO) and epicardial aspects (EPI) of the 
preparation. Each preparation was paced at a cycle length of 800 msec. 
Results: Saddle-back and coved types of ST elevation were observed after administra- 
tion of a low (<51Jmol/L) and high doses (>8p.mol/L) of pilsicainide (a pure Na ÷ channel 
blocker), respectively, to the pertusion blood in addition to pinacidU (201Jmol/L). In 4 prep- 
arations, polymorphic ventricular tachycardia (V'I') developed after an extrasystole spon- 
taneously occurring from EPI at the middle of repelarization phase of the preceding beat. 
Activation map during the initial phase of v'r revealed unstable reentry between ENDO 
and EPI with migrating functional block (Figure). 
Conclusion: Thus, VT in this "Brugada syndrome model" was initiated by phase 2 reen- 
try in EPI and subsequent unstable reentry between ENDO and EPI. 
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857-4 Incidence of Patients at High Risk of Sudden Death 
Among Patients Referred for  the Suspicion of a 
Brugada-Syndrome: A Prospective Study in 35 
Consecutive Patients With Brugada-Like ECG Changes 
Constanze M. Echternach, Martin Borggrefe, Susanne Spahl, Ayse Bilbal, Michael 
Junker, Juergen Kuschyk, Tim S0selbeck, Karl K. Haase, Christian Wolpert, DepL of 
Cardiology, University Clinic Mannheim, University of Heidelberg, Mannheim, German~ 
Background: Since the Brugeda-like ECG changes are now familiar to a larger number of 
physicians, referral to specialized arrhythmia clinics for further diagnosis and risk stratifi- 
cation of patients presenting with an abnormal ECG in V1 to V3 is increasing. However, 
since the patients are very heterogenous with respect to family history, symptoms and 
age and sex, decision finding especially in asymptomatic patients remains still very diffi- 
cult, The aim of the study was to assess prospectively the incidence of patients with Bru- 
geda-like ECG changes who are at high risk according to the consensus in consecutive 
patients. Patients and methods: A total of 35 patients were referred to our arrhythmia unit 
for abnormal ECG in leads V1 to V3, 19/35 were of male sex. 12 patients had a history of 
syncope, 4 patients palpitations, 3 patients had aborted sudden death, two patients a car 
accident with non-observed loss of consciousness and 5 patients a positive family history 
of sudden death. All patients underwent ajmaline test, 6 patients additional flecainide 
test, 15 patients electrophysiological study. Results: Ajmaline test was positive in 12/35 
patients. In the 6 patients in whom ajmaUns test was positive, flecainide test was positive 
as well. 3/15 patients with a positive ajmaline test had inducible polymorphic VT or VF in 
the programmed stimulation. All of these patients had syncope and/or a positive family 
history. All three patients were implanted a csrdioverter-defibrillator. Device data storage 
did not reveal any v r  or VF events during a mean follow-up of 5 months. Conclusions: 1. 
The incidence of patients at high risk of sudden death among consecutive patients 
referred for Brugada-like changes in the surface ECG is 3/35 in the present observation. 
2. This justifies a full work up including invasive electrophysiological testing. 3. All 
patients who were inducible had either a positive family history or syncope. 
11:30 a.m. 
857-5 Clinical Noninvasive- lnvasive Evaluation and Five-Year 
Follow-Up in Patients With the Brugads Syndrome: A 
Prospective Excel-Access Database 
Franco NaccareHa, Giovannina Lepera, Stafano Maranga, Cardiologia Azienda USL 
Citt~ di Bologna, Bologna, Italy, Cardiology Herman Hospital Houston, Houston, Texas. 
PURPOSE. The Brugada Sindrome (BS) is characterized by clinical, ECG and pheno- 
type differences, the genetic characterization of which has not been completely per- 
formed. Furthermore, prognostic differences have been described in subjects suffering 
from a previous cardiac arrest (PCA), ECG abnormalities in rest condition (ECG R) or 
after flecainide infusion (ECG F), inducibility of major ventricular arrhythmias (IND.VA) at 
PES, syncopal episodes (SE) without evidence of VA. 
METHODS. To this purpose, we evaluated 64 subjects, belonging to nine different fami- 
lies suffering from BS, 7/9 with a proband member affected by PCA, 1/9 with VT, and the 
last one without IND VA. Patients with PCA were treated with an ICD, one patient with VT 
received Amiodarone (A). Patients with dubious ECG received Flecainide 1.5 (1-2) mg/ 
Kg infusion (FT). Results are reported in the following table, according to different 
aspects and symptoms of the disease, considering recurrences of CA, syncopal epi- 
sodes (SE) in a follow up (FUP) of 42 ± 12 months. 
CONCLUSIONS. 1) Different clinical evolutions over time can be observed in patients 
with the Brugada Syndrome and specific clinical features to begin with. 2) Mainly patients 
with CA and SE show the worst prognosis. 3) Normal ECG in asymptomatic patients with 
a negative FT are associated with a benign prognosis. 4) The role of FT and IND. VA at 
PES should be furtherly evaluated. 
OBS. RESULTS FUP CA 
PCA 7/9 7/7 (ICD) 2/7 2/7 
VT 1/9 1/1 (IND. VA) 1/1 0/1 
NO VTNF 1/9 0/1 (IND. VA) 1/t 0/1 
SE 9/64 3/9 (IND. VA) 3/3 2/3 
ECG R DUBIOUS 7/64 7/7 (+ FT) 
(IND VA) 3/7 (IND. VA) 3/3 1/3 
ECG R ATYPICAL 18/64 2/18 (+ FT) 
(non IND VA) 0/2 (IND. VA) 0/2 
11:45 a.m. 
857-6 Ajmaline Versus Procainamide Challenge Test in the 
Diagnosis of Sudden Unexplained Death or Brugada 
Syndrome 
Gumoanart Veerakul, Lertlak Chaothawee, Banharn Koanantakul, Koonlawee 
Nademanse, Cardiovascular Research Center, Bhumibol Adutyadej Hospital, RTAF, 
Bangkok, Thailand, Pacific Rim Electrophysiology Research Institute, Inglewood, 
California. 
Sudden Unexplained Death Syndrome (SUDS), is characterized by an abnormal ECG 
with ST-elevation in V1-V3 and sudden death, similar to that seen in the Brugeda syn- 
drome. But the ECG marker waxes and wanes and may be normal at the initial presenta- 
